Blood Transfusion Process and Nursing Management of Children with Transfusion Dependent Thalassemia in COVID-19 Pandemic

Öz

Objective: The COVID-19 outbreak started in Wuhan, China in late 2019 and continues to spread globally. Since the emergence of COVID-19, the number of blood donations has decreased significantly both in our country and around the world. For those who require regular blood transfusion treatment, the decrease in blood donations is a serious concern. In some countries, it is stated that almost half of the children with transfusiondependent thalassemia receive inadequate blood transfusion. Due to the curfews and intercity transportation barriers in Turkey, children and their parents have difficulty in visiting clinics where they receive routine care for blood transfusion. In addition, these restrictions drastically reduced the number of voluntary blood donations, resulting in a significant shortage in blood stocks. During the blood transfusion process of children with thalassemia; social distance rules were observed, masks were worn, patient appointments were limited, and attendants were restricted. Nurses and patients used disposable materials, and nurses used protective equipment. With the emergence of COVID-19, children with transfusion-dependent thalassemia may experience difficulties in the treatment and care process due to reduced blood reserves. Thus, in a future crisis like the COVID-19 pandemic, the case of transfusion-dependent patients should be prioritized in the public health preparedness strategy, especially in countries where thalassemia is common.

Anahtar Kelimeler

• COVID-19
• thalassemia
• child
• nursing

COVID-19 Pandemisinde Transfüzyona Bağımlı Talasemili Çocukların Kan Transfüzyon Süreci ve Hemşirelik Yönetimi

Öz

Amaç: COVID-19 salgını 2019’un sonlarında Çin’in Wuhan kentinde başlamış olup küresel olarak yayılmaya devam etmektedir. COVID-19’un ortaya çıkmasından bu yana kan bağışı sayısı ciddi oranda hem ülkemizde hem de dünya genelinde azalmıştır. Düzenli kan transfüzyonu tedavisi gerektirenler için de kan bağışlarının azalması ciddi bir endişe kaynağı oluşturmaktadır. Bazı ülkelerde transfüzyona bağımlı talasemili çocukların neredeyse yarısına yetersiz kan transfüzyonu uygulandığı belirtilmektedir. Ülkemizdeki sokağa çıkma yasakları, şehirlerarası ulaşım engelleri nedeni ile çocuklar ve ebeveynleri kan transfüzyonu için rutin bakım aldıkları kliniklere gitmekte zorluk yaşamaktadır. Ayrıca bu kısıtlamalar, gönüllü kan bağışlarının sayısını büyük ölçüde azaltarak, kan bankalarının stoklarında ciddi oranda azalmaya neden olmuştur. Talasemili çocukların kan transfüzyonu sürecinde; sosyal mesafe kurallarına dikkat edilmiş, maske takılması sağlanmış, hasta randevuları sınırlandırılmış, refakatçi sınırlaması yapılmıştır. Hemşireler, hastalarda tek kullanımlık malzemeler kullanmış ve hemşireler koruyucu ekipman kullanmıştır. COVID-19’un ortaya çıkmasıyla transfüzyona bağımlı talasemili çocuklar, kan rezervlerinin azalmasına bağlı olarak tedavi ve bakım sürecinde güçlük yaşayabilmektedir. Buna bağlı olarak gelecekte, COVID-19 pandemisi gibi bir kriz sırasında halk sağlığı hazırlık stratejisinde, özellikle talasemiye yatkın ülkelerde transfüzyon bağımlı hastalar konusuna öncelik verilmelidir.

Anahtar Kelimeler

• COVID-19
• Talasemi
• Çocuk
• Hemşirelik

Kaynakça

1. Jiatongand S, Wenjun L. Epidemiological characteristics and prevention and control measures of CoronaVirusDisease 2019 in children. J Trop Med. 2020;20 (2):153‐6.
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
3. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. Med Rxiv (PrePrint). 2020.
4. Wu Z, McGoogan J. M.Characteristics of and important lessons from the coronavirus disease 2019 (covid‐ 19) outbreak in China. Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323 (13):1239-42,
5. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Carducci FIC, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child and Adolescent Health. 2020; 4(9): 653-61.
6. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impacton 1590 patients with Covid-19inChina:a nation wide analysis. Eur Respir J. 2020;55: 2000547.
7. Taher AT, Bou‐Fakhredin R, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations. Am J Hematol. [Preprint].2020 [cited 2020Nov 9]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272998/pdf/AJH-9999-na.pdfDOI: 10.1002/ajh.25857
8. Roy NBA, Telfer P, Eleftheriou P, de la Fuente J, Drasar E, Shah F, et al. Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. Br J Haematol.2020;189: 635– 9.

9. Galanello R, Origa R. Beta-thalassemia. Orphan J Rare Dis. 2010;5:11.
10. Kılınç Y. Hemoglobin hastalıkları: Talasemi. İçinde: Pediatrik hematoloji. Anak S.S, Aydoğan G, Çetin M, İrken G, Kemahlı S, Öztürk G, Yeşilipek MA, editörler. İstanbul: İstanbul Tıp Kitabevi; 2011.
11. Canatan D. Talasemi ve hemoglobinopatilerin Dünyada ve Türkiyede durumu. Türkiye Klinikleri J Hem Onc-Special Topics. 2010;3(1):1-4.
12. 1Canatan D. Türkiye’de hemoglobinopatilerin epidemiyolojisi. Hematolog 2014; 4:11-22.
13. Aydınok Y, Oymak Y, Atabay B, Aydoğan G, Yeşilipek A, Ünal S, et al. A National Registry of Thalassemia in Turkey: demographic and disease characteristics of patients, achievements, and challenges in prevention. Turk J Haematol. 2018;35(1):12-18.
14. Canatan D, Aydınok Y. Talasemi ve hemoglobinopatiler. Tanı ve tedavi. Antalya: Retma Matbaa; 2017: 29-34.
15. Nakavachara P, Viprakasit V. Adrenal insufficiency is prevalent in HbE/β-thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement. Clin Endocrinol.2013; 79:776– 83.
16. Thalassaemia International Federation. The covid–19 pandemic and haemoglobin disorders. 2020 [cited 2020 Nov 9]. Available from: https://thalassaemia.org.cy/wp-content/uploads/ 2020/03 / COVID-19-pandemic-and-haemoglobin-disorders_V2. pdf.
17. Motta I, Migone De Amicis M, Pinto VM, Balocco M, Longo F, Bonetti F, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience.AmJHematol. 2020; 95 (8): 188-189. 18. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med.2006; 3:343.
18. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet.2020: 395 473–5.
19. Shah N, Mishra A, Chauhan D, Vora C, Shah NR. Study on ectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. Asian J Transfus Sci. 2010 Jul; 4(2): 94-98.
20. Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S, et al. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet J Rare Dis.2017; 12:93.
21. Shander A, Goobie SM, Warner MA, Aapro M, Bisbe E, Perez- Calatayud AA, et al. Essential role of patient blood management in a pandemic: a call foraction. Anesth Analg. 2020 [cited 2020 Nov 9]. Avaible from: doi: 10.1213/ANE.0000000000004844.[Epub ahead of print]. DOI: 10.1213/ANE.0000000000004844.
22. https://www.kizilay.org.tr/ . [Internet]. Kan hizmetleri. [cited 2020 Sep 30]. Available from: https://www.kizilay.org.tr/neler-yapiyoruz/kan-hizmetleri
23. https://timesofindia.indiatimes.com. [Internet]. Covid-19: Lockdown creates acute shortage at blood banks. [cited 2020 Sep 30]. Available from: https:// timesofindia.indiatimes.com/india/ covid-19-lockdown-creates-acute-shortage-at-bloodbanks/articleshow/74958205.cms.
24. Karimi M, Haghpanah S, Zarei T, Azarkeivan A, Shirkavand A, Matin S, et al. Prevalence and severity of Coronavirus disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β-thalassemia patients and e ects of associated comorbidities: an Iranian nationwide study. Acta biomed. 2020; 91(3): e2020007.
25. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev [Internet]. 2020 [cited 2020 Nov 9]. Available from: https:/ /linkinghub.elsevier.com/retrieve/pii/S0887796320300146. DOI:https://dx.doi.org/10.1016%2Fj. tmrv.2020.02.003
26. Chowdhury SF, Anwar S. Management of Hemoglobin Disorders During the COVID-19 Pandemic. Front. Med.2020; 7:306.doi.org/10.3389/fmed.2020.00306
27. www.dhakatribune.com [Internet]. Thalassemia in the Time of Coronavirus. [cited 2020 Nov 9]. Available from: https://www.dhakatribune.com/opinion/op-ed/2020/ 05/07/thalassemia-in-the-time-of-coronavirusfbclid=IwAR32arCiy_XCbogEavveohlBZ3NpJJOa8Q5yJBgyhmr22QVp3EBuM0TNSCo (accessed September 30, 2020).
28. Hossain MS, Raheem E, Siddiqee MH. The forgotten people with thalassemia in the time of COVID-19: South Asian perspective. Orphanet J Rare Dis. 2020; 15(1): 1-2.